Akimitsu Maeda
YOU?
Author Swipe
View article: Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)
Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002) Open
Background: Olaparib and niraparib (poly adenosine diphosphate [ADP]-ribose polymerase [PARP] inhibitors) have significant antitumor action in patients with ovarian cancer. However, the incidence of nausea and vomiting among patient…
View article: Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer Open
Chemotherapy-induced neutropenia (CIN) is a dose-limiting factor for cytotoxic chemotherapy, but recently, it was suggested that CIN contributes to prolonged survival. In this study, we examined the association between severe CIN and survi…
View article: Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial Open
Olanzapine 5 mg did not show the expected effect on the complete disappearance of breakthrough chemotherapy-induced nausea and vomiting within 24 h.
View article: Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer Open
View article: Investigation of the Exposure of Preparation Gloves to a Cyclophosphamide Preparation using Equashield<sup>®</sup>
Investigation of the Exposure of Preparation Gloves to a Cyclophosphamide Preparation using Equashield<sup>®</sup> Open
Equashield® is a closed-system drug-transfer device (CSTD); it comprises a closed plunger and a barrel and is effective for decreasing the exposure of a syringe plunger to anti-cancer drugs. The protection of the syringe plunger has been s…
View article: Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin Open
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
View article: Issue Information
Issue Information Open
No abstract is available for this article.
View article: Investigation of Syringe Plunger Pollution with the Cyclophosphamide Preparation
Investigation of Syringe Plunger Pollution with the Cyclophosphamide Preparation Open
Use of a closed system drug transfer device is effective in decreasing the exposure of medical staff to anti-cancer drugs. However, the exposure of a syringe plunger to anti-cancer drugs during preparation has not been validated. Therefore…